Combined schedule of fludarabine and alemtuzumab followed by maintenance with low-dose alemtuzumab is effective for patients with progressive B-cell chronic lymphocytic leukemia.

被引：0
|
作者：
Kowal, M
Nowak, W
Nowaczynska, A
Dmoszynska, A
Skotnicki, AB
机构：
[1] Jagiellonian Univ, Fac Med, Dept Haematol, Krakow, Poland
[2] Med Univ Lublin, Dept Haematooncol & Bone Marrow Transplantat, Lublin, Poland
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5048
引用
收藏
页码：343B / 344B
页数：2
相关论文
共 50 条
  • [41] Early estimates of safety for alemtuzumab combined with fludarabine for the treatment of relapsed/refractory B-cell chronic lymphocytic leukemia: Phase II multicenter study.
    Brown, Jennifer R.
    Stock, Wendy
    Katzen, Harvey I.
    Suarez, Agustin J.
    Lakhanpal, Shailendra
    Leis, Jose F.
    Flowers, Christopher
    BLOOD, 2006, 108 (11) : 336B - 336B
  • [42] Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-cell chronic lymphocytic leukemia.
    Hillmen, P
    Skotnicki, AB
    Robak, T
    Mayer, J
    Jaksic, B
    Vukovic, V
    Weitman, S
    BLOOD, 2004, 104 (11) : 687A - 687A
  • [43] Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901
    Byrd, John C.
    Peterson, Bercedis L.
    Rai, Kanti R.
    Hurd, David
    Hohl, Raymond
    Perry, Michael C.
    Gockerman, Jon
    Nattam, Sreenivasa
    Larson, Richard A.
    LEUKEMIA & LYMPHOMA, 2009, 50 (10) : 1589 - 1596
  • [44] Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Hainsworth, John D.
    Vazquez, Elizabeth R.
    Spigel, David R.
    Raefsky, Eric
    Bearden, James D.
    Saez, Ruben A.
    Greco, F. Anthony
    CANCER, 2008, 112 (06) : 1288 - 1295
  • [45] Reconstitution of the T cell repertoire following treatment with alemtuzumab in patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Rezvany, MR
    Tehrani, MJ
    Karlsson, C
    Lundin, J
    Rabbani, H
    Mellstedt, K
    Österborg, A
    BLOOD, 2005, 106 (11) : 837A - 837A
  • [46] Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia
    Osterborg, A
    Mellstedt, H
    Keating, M
    MEDICAL ONCOLOGY, 2002, 19 (Suppl 2) : S21 - S26
  • [47] Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia
    Anders Osterborg
    Hakan Mellstedt
    Michael Keating
    Medical Oncology, 2002, 19 : S21 - S26
  • [48] Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia:: long-term effects of fludarabine and alemtuzumab treatment
    Kiaii, Shahryar
    Choudhury, Aniruddha
    Mozaffari, Fariba
    Rezvany, Reza
    Lundin, Jeanette
    Mellstedt, Hakan
    Osterborg, Anders
    LEUKEMIA & LYMPHOMA, 2006, 47 (07) : 1229 - 1238
  • [49] Reply to 'Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia' by Dr Laurenti et al.
    Lundin, J.
    LEUKEMIA, 2007, 21 (08) : 1821 - 1821
  • [50] Reply to ‘Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia’ by Dr Laurenti et al.
    J Lundin
    Leukemia, 2007, 21 : 1821 - 1821
12345